Abstract
Fred Sanger developed technologies that won him two Nobel Prizes and revolutionized biological research. Yet, in spite of this record, the question has been raised as to whether, in the current scientific climate, he might be unsuccessful in obtaining a grant because of a productivity that would be viewed as too limited. In imagining how a National Institutes of Health study section today might treat a proposal from Sanger to sequence DNA, we can ask whether there are lessons from his career that suggest changes to the grant review process.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
